Tardive Dyskinesia

Researchers are investigating epilepsy-dyskinesia syndromes, which are rare genetic diseases causing both movement disorders and epilepsy in children. This multinational retrospective survey, supported by the International Parkinson and Movement Disorder Society, aims to collect detailed clinical and molecular data to better understand these conditions. The study focuses on identifying patterns in disease features, progression, and genetic links to improve knowledge and support precision medicine. The study collects previously recorded data from multiple countries, harmonizing information on clinical features, disease progression, age of onset, genetic variants, and coexisting neurological conditions. By standardizing this data, the survey addresses challenges in rare disease research like small, dispersed patient groups and inconsistent protocols. The goal is to build a shared clinical database and analyze how movement and seizure disorders relate at both clinical and molecular levels. Participants are children aged 0 to 18 years with diagnosed movement disorders linked to specific genetic variants. The study reviews existing medical records and genetic information without new treatments or interventions. Researchers will assess the disease spectrum, how movement disorders affect quality of life, and the effectiveness of symptomatic treatments over one year. The study encourages international collaboration to advance understanding and improve care for these rare conditions.

Researchers are evaluating the effectiveness of valbenazine in adults with tardive dyskinesia (TD) who continue to have symptoms while taking or after stopping a vesicular monoamine transporter 2 (VMAT2) inhibitor. This Phase 4 open-label study focuses on both clinician- and patient-reported outcomes to better understand valbenazine's impact on TD symptoms in participants with schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder. Participants will receive oral valbenazine capsules once daily for 24 weeks. The study monitors changes in involuntary movement using the Abnormal Involuntary Movement Scale (AIMS) and evaluates other measures related to disease severity and quality of life. This open-label treatment period allows all participants to receive the study drug without placebo comparison. During the study, participants will undergo assessments at baseline and Week 24 including movement evaluations, clinical global impression scores, and patient-reported impact and health-related quality of life scales. Researchers will track safety and tolerability throughout the 24-week treatment. Total participation time corresponds to the 24 weeks of daily valbenazine treatment and follow-up assessments.

This research focuses on isolated dystonia, a movement disorder that causes involuntary muscle contractions leading to abnormal twisting movements and postures. Diagnosing dystonia is challenging because there is no biomarker or gold standard test, resulting in frequent misdiagnoses and delays averaging over 10 years. The study aims to clinically validate DystoniaNet, a deep learning platform designed to improve the accuracy and speed of dystonia diagnosis through retrospective and prospective studies. The study consists of two parts: retrospective studies will validate DystoniaNet's diagnostic ability by comparing patients with dystonia to healthy individuals and to patients with other neurological or non-neurological conditions that mimic dystonia symptoms. The prospective randomized study will test DystoniaNet's performance for fast, objective diagnosis in actual clinical settings. The intervention involves using DystoniaNet as a diagnostic test to distinguish dystonia from similar disorders. Participants will undergo clinical evaluations and brain imaging data will be analyzed by the DystoniaNet algorithm to measure the correctness and speed of dystonia diagnosis over four years. Researchers will monitor diagnostic accuracy, time to diagnosis, and compare results across patient groups. This study aims to advance dystonia diagnosis to clinical practice, enabling earlier treatment and better patient outcomes, with participation lasting throughout the study period ending in 2028.

Researchers are evaluating the effectiveness of the drug NBI-1065890 compared with a placebo in treating adults with tardive dyskinesia (TD), a condition involving involuntary movements. This Phase 2 trial aims to assess the safety, tolerability, and impact of NBI-1065890 on TD symptoms in adults aged 18 to 75 years. Participants must have a medically confirmed diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder, along with neuroleptic-induced TD. In this randomized, double-blind study, participants will receive either NBI-1065890 or a matching placebo by mouth. The trial includes two groups: one taking the experimental drug and the other taking placebo. The study is designed to compare changes in abnormal involuntary movements over an 8-week period, with treatments administered during this time. The study uses blinded assessments to measure the severity of dyskinesia. Participants will undergo evaluations including video assessments of involuntary movements at the start and after 8 weeks of treatment. Researchers will measure changes in the Abnormal Involuntary Movement Scale (AIMS) total score and assess clinical improvement using standard rating scales. Safety and tolerability will be closely monitored. The total participation time includes screening and an 8-week treatment period, with follow-up assessments to capture treatment effects and side effects.

Researchers are studying epilepsy-dyskinesia syndromes, which include movement disorders and seizures linked to genetic causes. This observational study aims to collect long-term clinical data and biological samples from patients of all ages with a confirmed genetic diagnosis. By analyzing molecular and clinical information, the study hopes to uncover patterns that improve understanding of these complex conditions and support precision medicine and international collaboration. Participants will be part of a registry and natural history study where data on clinical features, disease progression, developmental history, functionality, treatment response, and genetic variants will be gathered. Biological samples like blood, urine, and tissue will be collected to establish a biobank. The study is designed to explore genotype-phenotype correlations, assess the impact of symptoms on quality of life, and evaluate treatments over a long period. During the study, participants will undergo regular clinical assessments and provide biological samples to help researchers measure disease characteristics, treatment effects, and quality of life. Outcomes include creating a biorepository, understanding the disease spectrum, assessing treatment effectiveness, and establishing readiness for future clinical trials. The study will last for at least five years, with ongoing monitoring and data collection to support these goals.

This research aims to validate and test the reliability of the Turkish version of the Parkinson's Disease Dyskinesia Scale (PDYS-26) for patients with idiopathic Parkinson's disease. Dyskinesia, which involves involuntary muscle movements, is a common motor complication in Parkinson's disease and can affect daily activities. The study evaluates how well this scale measures dyskinesia impact in Turkish-speaking patients and compares it with other assessments like the Tampa Kinesiophobia Scale, Mini BesTest, Activity Specific Balance Safety Scale, and Parkinson's Disease Questionnaire-39. Participants diagnosed with idiopathic Parkinson's disease who have a dyskinesia score of 1 or higher on the Unified Parkinson's Disease Rating Scale (UPDRS) will be involved. The PDYS-26 scale will be translated into Turkish using a back-translation method and finalized with expert approval. Patients will complete the adapted scale and other related assessments to determine its validity and reliability in the Turkish population. Participants will be assessed at baseline (Day 1) and again seven days later (Day 8) using the PDYS-26. The study includes evaluations through various questionnaires and scales to measure dyskinesia severity, balance, fear of movement, and quality of life. The research team will monitor the participants' responses to ensure the scale's effectiveness and relevance for use in clinical settings with Turkish Parkinson's patients.

Researchers are evaluating repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in people with Parkinson's Disease (PD). The study focuses on stimulating the pre-supplementary motor area (pre-SMA) to see if this can delay the start of dyskinesia after levodopa intake and reduce its severity. This research aims to identify the best rTMS targets, parameters, and understand the mechanisms behind LID in PD. Participants will receive rTMS bursts targeting the pre-SMA using a device called the MagVenture Cool-B70 coil. The study includes groups receiving real stimulation at gamma frequency (130Hz) or beta frequency (20Hz) and corresponding sham (inactive) stimulations for 30 minutes. The stimulation intensity and location will be optimized based on brain anatomy and electric field simulations. The study compares the effects of these different burst frequencies on LID symptoms. During the study, participants will be assessed using the Unified Dyskinesia Rating Scale (UDysRS) and monitored for the time dyskinesia begins after taking 150% of their usual morning levodopa dose. Movement symptoms will also be evaluated using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. A clinician unaware of the treatment group will perform ratings. The study follows a randomized, double-blind design and includes assessments up to 40 minutes after levodopa intake, with safety and response monitored throughout.

Tardive Dyskinesia (TD) is a movement disorder caused by long-term use of dopamine receptor blockers and related drugs. It results in involuntary movements that persist and cause lasting neurological damage, significantly impacting patients' daily functioning. Researchers are evaluating whether repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation technique, can improve motor symptoms in people with TD. This study focuses on a specific rTMS mode called continuous theta-Burst Stimulation (cTBS), which may offer more lasting benefits through precise brain targeting. Participants will receive rTMS treatment for 14 days using cTBS. Before treatment, they will undergo an MRI scan to create a personalized brain map, allowing precise localization of the stimulation areas in the motor and sensory networks. The study includes two groups: one receiving active rTMS and the other receiving sham (placebo) rTMS. This design allows comparison to assess the treatment's effect on TD motor symptoms under double-blind conditions. During the study, participants will be regularly assessed using the Abnormal Involuntary Movement Scale (AIMS) over two years to measure changes in abnormal movements. Researchers will monitor safety and treatment effects throughout this period. Participation involves MRI scans, rTMS sessions, and follow-up visits to evaluate motor symptoms and overall response to the intervention.

Researchers are exploring the effects of quitting smoking using varenicline on neurological side effects caused by antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. This 12-week pilot study focuses on 10 smokers with pre-existing tardive dyskinesia who are on stable antipsychotic medication doses. The goal is to find out if stopping smoking with varenicline can reduce these neurological symptoms without worsening other movement-related side effects. Participants will begin the study with a 2-week baseline period to monitor symptoms and smoking habits. Varenicline treatment starts at a low dose and increases over the first two weeks, continuing for the remaining 9 weeks. Participants must stop smoking completely by week 6 and will attend several clinic visits for medication checks and symptom assessments throughout the study. During the study, researchers will regularly assess smoking status using questionnaires and carbon monoxide breath tests. Neurological symptoms will be measured with several rating scales, including the Simpson-Angus Scale and Abnormal Involuntary Movement Scale. Additional evaluations include psychiatric symptoms, cognitive tests, pregnancy tests for women, and monitoring of medication adherence and adverse events. The main outcome is the participant's smoking abstinence at 12 weeks, along with changes in smoking amount and neurological side effects.